Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic Registries

• Published in: Journal of rheumatology Vol. 51; no. 11; p. 1111
• Main Authors: Provan, Sella Aarrestad, Ljung, Lotta, Kristianslund, Eirik Klami, Michelsen, Brigitte, Uhlig, Till, Jonmundsson, Thorarinn, Sexton, Joe, Gudbjornsson, Bjorn, Di Giuseppe, Daniela, Hetland, Merete Lund, Reynisdottir, Gudrun Bjork, Glintborg, Bente, Relas, Heikki, Aaltonen, Kalle, Kvien, Tore Kristian, Askling, Johan
• Format: Journal Article
• Language: English
• Published: Canada 01.11.2024
• Subjects: Adult; Aged; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis, Psoriatic - drug therapy; Arthritis, Psoriatic - epidemiology; Arthritis, Rheumatoid - complications; Arthritis, Rheumatoid - drug therapy; Arthritis, Rheumatoid - epidemiology; Biological Products - adverse effects; Biological Products - therapeutic use; Female; Follow-Up Studies; Humans; Incidence; Lung Diseases, Interstitial - epidemiology; Male; Methotrexate - therapeutic use; Middle Aged; Registries; Scandinavian and Nordic Countries - epidemiology; Scandinavian and Nordic Countries; methotrexate; psoriatic arthritis; interstitial lung disease; rheumatoid arthritis

Interstitial lung disease (ILD) is one of the most common pulmonary manifestations of rheumatoid arthritis (RA), but its prevalence has not been investigated in psoriatic arthritis (PsA). The role of methotrexate (MTX) in ILD development remains under debate. This study (1) compares the incidences o...